secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIxCrypto Holdings, Inc. (AIXC)
CIK:        0001460702
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001493152-23-028863
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Qualigen sells FastPack for ~$5M; Q2 loss narrows to $3.5M; FDA OK for QN-302 trial
--------------------------------------------------------------------------------

- Divested FastPack diagnostics to Chembio (BIOSYNEX) for ~$5M all cash; proceeds for therapeutics pipeline.
- FDA cleared IND for QN-302; Phase 1 trial in advanced solid tumors to start H2 2023, targeting 24+ patients in 2024.
- Q2 revenue $1.6M (+14% YoY); net loss $3.5M ($0.69/share) vs $4.1M ($1.12) in prior-year quarter.
- R&D spend $1.3M (89% on therapeutics); Pan-RAS platform on track for late in vivo candidate by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/0001493152-23-028863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer